v3.26.1
Stockholders' equity - Summary of Company's Outstanding Warrants Exercisable for Shares of Common Stock (Details)
Mar. 31, 2026
$ / shares
shares
2023 Common Warrants [Member]  
Liability classified warrants (Derivative Warrant Liabilities)  
Number of warrants (in Shares) | shares 0 [1]
Exercise price (in Dollars per share) | $ / shares $ 3.003 [1]
2023 Pre-funded Warrants [Member]  
Liability classified warrants (Derivative Warrant Liabilities)  
Number of warrants (in Shares) | shares 338,252
Exercise price (in Dollars per share) | $ / shares $ 0.0001
2025 Common Warrants [Member]  
Liability classified warrants (Derivative Warrant Liabilities)  
Number of warrants (in Shares) | shares 4,418,292 [2]
Exercise price (in Dollars per share) | $ / shares $ 3.395 [2]
2025 Pre-funded Warrants [Member]  
Liability classified warrants (Derivative Warrant Liabilities)  
Number of warrants (in Shares) | shares 907,708
Exercise price (in Dollars per share) | $ / shares $ 0.0001
[1] Following the exercise of 1,345,464 2023 Common Warrants in October 2025, the remaining 1,190,927 2023 Common Warrants expired on October 21, 2025, which was the 60th day after the date of the acceptance by the FDA of the NDA for the Company’s product candidate GTx-104.
[2] The 2025 Common Warrants will expire on the earlier of: (i) the 60th day after the date the FDA approves the NDA for GTx-104 and (ii) September 25, 2028.